Management of Myelodysplastic Syndrome Flare

Immediate Supportive Management

The European Society for Medical Oncology recommends transfusing RBC concentrates to maintain hemoglobin at least 8 g/dL, or 9-10 g/dL in patients with cardiovascular comorbidities or poor functional tolerance, to manage anemia in MDS patients 2, 3
Administering sufficient RBC units over 2-3 days if necessary to increase hemoglobin above 10 g/dL can limit chronic anemia effects on quality of life in MDS patients 2, 3
Rapid initiation of broad-spectrum antibiotics is mandatory for any fever or symptoms of infection in neutropenic MDS patients, according to the European Society for Medical Oncology 2, 3
G-CSF can be added during severe infections and improves neutropenia in 60-75% of cases, but prolonged prophylactic use has not demonstrated survival impact in MDS patients 2, 3, 5
Prophylactic platelet transfusions are generally not used long-term except in MDS patients receiving myelosuppressive drugs, as recommended by the European Society for Medical Oncology 3, 5
For severe thrombocytopenia with bleeding, providing platelet transfusions as clinically indicated is recommended for MDS patients 2

The International Working Group for MDS recommends performing complete blood count with platelets and repeating bone marrow examination if there is concern for disease progression to higher-risk MDS or AML transformation in MDS patients 1, 6
Reassessing IPSS-R risk category is crucial in determining whether treatment escalation is needed for MDS patients, according to the International Working Group for MDS 1
For patients experiencing a flare that represents progression to higher-risk disease, the European Society for Medical Oncology recommends azacitidine 75 mg/m² subcutaneously for 7 consecutive days every 28 days as the first-line reference treatment 1
At least 6 cycles of azacitidine are recommended for MDS patients, as most patients only respond after several courses, according to the European Society for Medical Oncology 1, 2
Allogeneic stem cell transplantation should be proposed to all fit MDS patients ≤70 years with higher-risk disease who have a donor, as this is the only potentially curative option, recommends the European Society for Medical Oncology 1, 3

Monitoring for citrate toxicity, such as hypocalcemia and hypomagnesemia, is essential if multiple transfusion units are given rapidly to MDS patients 4
Reassessing hemoglobin and symptoms after each transfusion unit is crucial in managing anemia in MDS patients 4
The European Society for Medical Oncology recommends not withholding G-CSF during active severe infection with neutropenia, even though prophylactic use is not recommended, for MDS patients 2, 3
Delaying broad-spectrum antibiotics in febrile neutropenic MDS patients is not recommended, as this is mandatory regardless of whether the flare represents disease progression, according to the European Society for Medical Oncology 2, 3
The European Society for Medical Oncology recommends individualizing hemoglobin thresholds between 8-10 g/dL based on clinical status, rather than transfusing to arbitrary targets, for MDS patients 2, 3